



ESETT Clinical Coordinating Center  
Neuro Emergencies Research  
University of Michigan

24 Frank Lloyd Wright Dr.  
Lobby H, Suite 3100  
Ann Arbor, MI 48106  
734-232-2142

**Trial Principal Investigators**

Jaideep Kapur, MD  
Robert Silbergleit, MD  
James Chamberlain, MD  
Jordan Elm, PhD

**NETT CCC/SDMC Principal Investigators**

Bill Barsan, MD  
Yuko Palesch, PhD  
Valerie Durkalski, PhD

**Leadership and Operations**

Valerie Stevenson, BAS, CCRP  
Daniel Lowenstein, MD  
Shlomo Shinnar, MD  
Hannah Cock, MD  
Erin Bengelink, MA, LLP  
Natalie Fisher, MS, CCRP  
Sonya A. Gunter, MS  
Catherine Dillon, CCRP  
Jodie Riley, MS  
Deneil Harney, MPH, MSW  
Joy Black, BSN, RN, MS

**National Institute of Neurological Disorders  
and Stroke Program Directors**

Adam L. Hartman, MD  
Robin Conwit, MD

**NETT Hub Principal Investigators**

Opeolu Adeoye, MD, MS  
Tom Aufderheide, MD  
Jill Baren, MD, MBE  
Michelle Birots, MD, MS  
Jan Claassen, MD, PhD  
Kurt Denninghoff, MD  
Nina Gentile, MD  
J. Claude Hemphill, III, MD, MAS  
Roger Humphries, MD  
Elizabeth Jones, MD  
Christopher Lewandowski, MD  
Joseph P. Ornato, MD  
James V. Quinn, MD  
Barney J. Stern, MD  
Craig Warden, MD, MPH  
Robert Welch, MD  
David Wright, MD

**PECARN Site Principal Investigators**

Lynn Babcock, MD, MS  
Kathleen Brown, MD  
Daniel Cohen, MD  
Robert Hickey, MD  
Maija Holsti, MD, MPH  
Lisa Merck, MD, MPH  
Pamela Okada, MD  
Claire Pearson, MD  
Alexander Rogers, MD  
Dale Steele, MD, MS  
Danny Thomas, MD, MPH  
Cheryl Vance, MD

**Date:** 28 January 2019  
**To:** Participating Sites  
**From:** Study Leadership  
**Re:** End of Enrollment

This memo provides formal notification that all enrollment in the ESETT study is now complete as we have met a pre-planned stopping boundary on an interim analysis.

After placing enrollment on voluntary hold earlier this month, the study leadership asked the DSMB to consider performing the next interim analysis 22 subjects early as part of our preventative action plan. After agreeing, and then reviewing the interim analysis report, the NIH/NINDS appointed ESETT DSMB recommended to NINDS that the trial be closed because the pre-specified stopping criterion has been met. NINDS concurred with this recommendation.

The DSMB and the NINDS have conveyed their thanks to all of the trial's study teams for their hard work in completing this important trial.

We will separately communicate further instructions about next steps. Thank you again for your hard work and diligence in support of this study.

